- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02863757
Follow-up of Chronic Hepatitis B Patients With Comorbid Nonalcoholic Fatty Liver Disease
December 19, 2022 updated by: Humanity and Health Research Centre
Disease Progression and Clinical Outcomes in Chronic Hepatitis B (CHB) Patients With Comorbid Nonalcoholic Fatty Liver Disease (NAFLD)
The purpose of this study is to determine the disease progression in CHB/NAFLD compared with CHB and NAFLD including liver cirrhosis, cirrhotic complications and hepatocellular carcinoma (HCC).
Study Overview
Status
Recruiting
Study Type
Observational
Enrollment (Anticipated)
1500
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: George Lau, MD
- Phone Number: +852 2861 3777
- Email: gkklau@netvigator.com
Study Locations
-
-
Hong Kong
-
Hong Kong, Hong Kong, China, 00852
- Recruiting
- Humanity and Health GI and Liver Centre
-
Contact:
- George KK Lau, MD
- Phone Number: (852)28613777
- Email: gkklau@netvigator.com
-
Principal Investigator:
- George KK Lau, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Hosptials and primary care clinics
Description
Inclusion Criteria:
- Liver biopsy proved CHB and/or NAFLD at baseline;
- Chinese
- Follow-up duration>12 months
Exclusion Criteria:
- Other liver diseases;
- Secondary causes of hepatic steatosis;
- Alcohol abuse;
- Liver cirrhosis, cirrhosis related complications or HCC at baseline;
- Malignancy;
- History of liver transplantation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
---|
CHB Group
Patients with chronic hepatitis B
|
CHB/NAFLD Group
Patients with chronic hepatitis B and comorbid nonalcoholic fatty liver disease
|
NAFLD Group
Patients with nonalcoholic fatty liver disease
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of patients with liver cirrhosis, hepatic encephalopathy, esophageal varices, ascites and hepatocellular carcinoma
Time Frame: Up to 20 years
|
Up to 20 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of patients with hypertension, obesity, diabetes mellitus, hyperlipidaemia
Time Frame: Up to 20 years
|
Up to 20 years
|
Number of patients with liver transplantation and liver-related death
Time Frame: Up to 20 years
|
Up to 20 years
|
Diagnosis time of liver cirrhosis, hepatic encephalopathy, esophageal varices, ascites and hepatocellular carcinoma from baseline
Time Frame: Up to 20 years
|
Up to 20 years
|
Occurrence time of liver transplantation and liver-related death from baseline
Time Frame: Up to 20 years
|
Up to 20 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2016
Primary Completion (Anticipated)
December 1, 2026
Study Completion (Anticipated)
December 1, 2026
Study Registration Dates
First Submitted
August 4, 2016
First Submitted That Met QC Criteria
August 8, 2016
First Posted (Estimate)
August 11, 2016
Study Record Updates
Last Update Posted (Actual)
December 21, 2022
Last Update Submitted That Met QC Criteria
December 19, 2022
Last Verified
December 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Hepatitis, Viral, Human
- Hepadnaviridae Infections
- DNA Virus Infections
- Enterovirus Infections
- Picornaviridae Infections
- Liver Diseases
- Hepatitis B
- Hepatitis
- Hepatitis A
- Fatty Liver
- Hepatitis B, Chronic
- Hepatitis, Chronic
- Non-alcoholic Fatty Liver Disease
Other Study ID Numbers
- H&H_NAFLD/CHB
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Hepatitis B
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Gilead SciencesNot yet recruiting
-
Tongji HospitalGilead SciencesRecruiting
-
Jiangsu HengRui Medicine Co., Ltd.Unknown
-
Changhai HospitalCompleted
-
Tongji HospitalChia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownChronic Hepatitis b
-
Zhongshan Hospital Xiamen UniversityUnknownHealthy | Chronic Hepatitis B InfectionChina
-
Brii Biosciences LimitedVir Biotechnology, Inc.Active, not recruitingChronic Hepatitis B Virus InfectionSingapore, Thailand, Australia, China, Korea, Republic of
-
Nanfang Hospital of Southern Medical UniversityRecruiting
-
IlDong Pharmaceutical Co LtdRecruitingChronic Hepatitis bKorea, Republic of